Patent: 9,592,288
✉ Email this page to a colleague
Summary for Patent: 9,592,288
Title: | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
Abstract: | The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided. |
Inventor(s): | Schultz; Peter (La Jolla, CA), Lairson; Luke (San Diego, CA), Deshmukh; Vishal (La Jolla, CA), Lyssiotis; Costas (Boston, MA) |
Assignee: | The Scripps Research Institute (La Jolla, CA) IRM LLC (Hamilton, BM) |
Application Number: | 13/985,342 |
Patent Claims: | see list of patent claims |
Details for Patent 9,592,288
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bayer Healthcare Pharmaceuticals Inc. | BETASERON | interferon beta-1b | For Injection | 103471 | 07/23/1993 | ⤷ Try a Trial | 2031-02-18 |
Biogen Inc. | AVONEX | interferon beta-1a | For Injection | 103628 | 05/17/1996 | ⤷ Try a Trial | 2031-02-18 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 05/28/2003 | ⤷ Try a Trial | 2031-02-18 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 02/27/2012 | ⤷ Try a Trial | 2031-02-18 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2031-02-18 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2031-02-18 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |